Apixaban bests rivaroxaban in lowering rates of recurrent VTE and bleeding: Study
Ghadeer K. Dawwas and colleagues have found in a new study that patients with venous thromboembolism (VTE) who were new users of apixaban had lower rates of recurrent VTE and bleeding than new users of rivaroxaban.
This study was published in Annals of Internal Medicine on 7th December, 2021.
Apixaban and rivaroxaban are taking the place of vitamin K antagonists in the treatment of VTE in adults; however, head-to-head comparisons are still limited, therefore this study was conducted by researchers. To compare the efficacy and safety of apixaban versus rivaroxaban in patients with VTE.
From 1 January 2015 to 30 June 2020, a retrospective new-user cohort study was conducted in a commercial health care insurance database in the United States. Adults with VTE who had recently been prescribed apixaban or rivaroxaban were recruited for this study. The primary efficacy outcome was recurrent VTE, which was a combination of deep venous thrombosis and pulmonary embolism. The primary safety outcome was a combination of GI and intracranial bleeding.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.